RecruitingPhase 2Drug trialMycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung DiseaseThe goal of this pilot study is to assess the feasibility of a larger study on the efficacy of mycophenolate mofetil in people diagnosed with systemic sclerosis with mild lung involvement. Participants will be recruited over 12 months at 3 academic centers and assigned randomly to receive either mycophenolate mofetil or placebo, a look-alike substance that contains no active drug, for 96 weeks.